240 related articles for article (PubMed ID: 18195094)
1. Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations.
Li S; Kralovics R; De Libero G; Theocharides A; Gisslinger H; Skoda RC
Blood; 2008 Apr; 111(7):3863-6. PubMed ID: 18195094
[TBL] [Abstract][Full Text] [Related]
2. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
[TBL] [Abstract][Full Text] [Related]
3. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis.
Cazzola M
Haematologica; 2007 Dec; 92(12):1585-9. PubMed ID: 18055979
[No Abstract] [Full Text] [Related]
5. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis.
Ohyashiki JH; Hisatomi H; Shimizu S; Sugaya M; Ohyashiki K
Jpn J Clin Oncol; 2009 Aug; 39(8):509-13. PubMed ID: 19491085
[TBL] [Abstract][Full Text] [Related]
6. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
7. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Maddali M; Kulkarni UP; Ravindra N; Jajodia E; Arunachalam AK; Suresh H; Venkatraman A; George B; Mathews V; Balasubramanian P
Ann Hematol; 2020 May; 99(5):983-989. PubMed ID: 32277273
[TBL] [Abstract][Full Text] [Related]
8. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
9. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.
Dupont S; Massé A; James C; Teyssandier I; Lécluse Y; Larbret F; Ugo V; Saulnier P; Koscielny S; Le Couédic JP; Casadevall N; Vainchenker W; Delhommeau F
Blood; 2007 Aug; 110(3):1013-21. PubMed ID: 17389763
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
11. Imatinib effect on growth and signal transduction in polycythemia vera.
Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
[TBL] [Abstract][Full Text] [Related]
12. Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.
Swierczek SI; Yoon D; Bellanné-Chantelot C; Kim SJ; Saint-Martin C; Delhommeau F; Najman A; Prchal JT
Haematologica; 2011 May; 96(5):775-8. PubMed ID: 21273266
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
14. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and laboratory features compared between JAK2 exon12 and JAK2 V617F mutated polycythemia vera].
Liu D; Zhang PH; Xu ZF; Ma J; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Jia YJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):107-114. PubMed ID: 35381670
[No Abstract] [Full Text] [Related]
17. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
[TBL] [Abstract][Full Text] [Related]
18. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
[TBL] [Abstract][Full Text] [Related]
19. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera.
Schnittger S; Bacher U; Haferlach C; Geer T; Müller P; Mittermüller J; Petrides P; Schlag R; Sandner R; Selbach J; Slawik HR; Tessen HW; Wehmeyer J; Kern W; Haferlach T
Haematologica; 2009 Mar; 94(3):414-8. PubMed ID: 19252176
[TBL] [Abstract][Full Text] [Related]
20. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
